Seres Therapeutics, Inc. - Common Stock (MCRB)

Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Seres (MCRB) Q3 2025 Earnings Call Transcript

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Seres Therapeutics reports Q2 2025 results with $0.0 revenue and a narrower EPS loss of $2.27, beating estimates. Shares dip 4.5% pre-market despite recent 23% gain. Progress noted in SER-155 clinical trials.

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.